Earnings Preview: What To Expect From Edwards Lifesciences' Report
By Kritika Sarmah
Meril TAVR valves linked to 1-year outcomes similar to industry-leading devices from Medtronic, Edwards
By Michael Walter
Edwards Lifesciences Stock Jumps On A Setback For Boston Scientific
By Allison Gatlin
Intra-annular TAVR valves from Edwards Lifesciences and Abbott deliver similar 1-year outcomes
By Michael Walter
Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis
By Heather Bukant
Q&A with Darshin Patel, who led the Edwards Lifesciences Sapien M3 TMVR system's development
By Jim Hammerand
Edwards Lifesciences paid Zovighian $15M for first year as CEO
By Jim Hammerand
Edwards Lifesciences Corporation (EW): Jim Cramer Says It's a Hold — But Is Boston Scientific Now His Favorite?
By Dionysis Partsinevelos
New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients
By Heather Bukant
Q&A with nitinol expert Ming Wu: Manufacturing, testing and more
By Jim Hammerand
Edwards Lifesciences Veteran Katie Szyman Named Next Masimo CEO
By Yuika Yoshida
First-in-class SAVR valve from Edwards Lifesciences linked to positive 5-year outcomes
By Michael Walter
Edwards Lifesciences scores a win at CMS for TTVR
By Danielle Kirsh
On the Move: Melissa Hoffman, Vice President at Edwards Lifesciences Joins Easterseals Southern California Board of Directors
By Mia Laureys
Edward Lifesciences: A Closer Look At Growth And Valuation
By Daniel Schonberger
Meril successful at EPO against Edwards Lifesciences in heart-valve battle
By Konstanze Richter
Edwards Lifesciences’ Q4 2024 Earnings: What to Expect
By Neha Panjwani
EW INVESTOR ALERT: Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
By Robbins Geller Rudman
Edwards Lifesciences Announces EARLY TAVR Trial Results
By Rachel Klemovitch
Integra Lifesciences appoints new chief quality officer
By Danielle Kirsh
EDWARDS LIFESCIENCES has been Sued for Securities Fraud
By Bleichmar Fonti
Edwards Lifesciences gains amid takeover speculation
By Joshua Fineman
S&P 500 Gains and Losses Today: Edwards Lifesciences Sinks on Outlook for Key Product
By Michael Bromberg
Edwards Lifesciences acquires JC Medical from Genesis Medtech
By Joshua Silverwood
Movers & Shakers: Grant Thornton, United Drug, Edwards Lifesciences, Fine Grain, Viatel, Kepak, EU Commission
By Peter O' Dwyer